Wall Street is betting tens of millions of dollars on psychedelic drugs that backers say could treat mental illness for a fraction of what it costs to do therapy with better-known treatments.
Transcend Therapeutics Inc. raised $40 million from venture-capital investors in January to develop a post-traumatic stress disorder treatment that its 29-year-old CEO Blake Mandell says would require about half the amount of therapy as MDMA, or ecstasy, a popular hallucinogen. Gilgamesh Pharmaceuticals Inc. and Lusaris Therapeutics Inc. have announced capital raises of about $100 million since November for similar products addressing depression.
24World Media does not take any responsibility of the information you see on this page. The content this page contains is from independent third-party content provider. If you have any concerns regarding the content, please free to write us here: contact@24worldmedia.com
Seth Masket The Democrats have some tough choices in front of them. With Vice President Kamala Harris,...
AYER — On Nov. 18 of last year, Lynnfield’s boys soccer team captured the Division 4 state...
Editorial written by the New York Daily News Editorial Board. Get ready to welcome back polio and welcome...
MARBLEHEAD — While negotiations continued in Marblehead Tuesday morning at 10:30 a.m., as usual, some...
WOBURN — Bragging rights. For all the marbles. May the best team win. However you wanted to say it,...
All address information, particularly arrests, reflects police records. In the event of a perceived...
Peabody starts to plan new high school
LTTE: Lynnway bike lane concerns
Nahant teachers agree to deal
Item Santa needs your help
Southold runners post personal records at New York state championships
Raymond Bastarache receives Community Unsung Hero Award
Saugus Middle High School upcoming winter concerts
Sweeping climate bill passes the Massachusetts Legislature
Flames break out again in Saugus
Robert Earle McCall – The Suffolk Times
LTTE: Urging Moulton to support trans youth
LTTE: The price of power